Phase I/II study of RT002 for treatment of muscle movement disorders

Trial Profile

Phase I/II study of RT002 for treatment of muscle movement disorders

Planning
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Movement disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2015 New trial record
    • 12 Jan 2015 According to a Revance Therapeutics media release, information on selected indication and trial design will be provided in the first half of 2015 and related clinical results will be reported in the second half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top